Document text
Principal Investigator: Robert Turner Schooley
Organization: UNIVERSITY OF CALIFORNIA, SAN DIEGO
Fiscal Year: 2021
Award: $169,785
Funding agency: National Institute of Allergy and Infectious Diseases
Since the emergence of SARS CoV-2 in China in the fall of 2019, nearly 200 million cases of COVID-19 have been reported globally; over 4 million of these individuals have died. In the US, the virus has been responsible for over 600,000 deaths. Despite a good understanding of non-pharmaceutical interventions that mitigate viral transmission and the development of several highly efficacious vaccines, the global epidemic has continued at a brisk pace. Vaccine availability has been scant in resource limited settings and, even where it has been widely available for months, substantial segments of the public have declined vaccination. In addition, as new more transmissible viral variants emerge that are less susceptible to immunity stimulated by first generation vaccines, an increasing number of breakthrough infections have been noted. Although most of these breakthrough infections do not result in hospitalization, some do, and there is a significant concern that further immunological evolution will further compromise vaccine efficacy. Although further progress on the vaccine front is to be expected, highly effective and well tolerated antiviral agents are sorely needed. At present, the only two modes of antiviral therapy currently approved by the US Food and Drug Administration are Remdesivir and monoclonal antibodies directed at the viral spike protein. Both of these therapeutic modalities require parenteral administration, greatly limiting their general utility, especially in resource limited settings. In addition, as the viral spike protein has evolved within the human population, several of the monoclonals have lost their efficacy against new circulating viral variants. This evolution is expected to continue as critical viral epitopes are shaped by human immune responses generated during natural infection. In this supplement, we propose to apply our synthetic chemistry to the remdesivir base and other nucleosides to develop well-tolerated compounds with high levels of activity against the RNA polymerase of SARS CoV-2 and other coronaviruses that can be delivered orally and achieve uniformly therapeutic concentrations of the active triphosphate in a wide variety of relevant tissue types. If successful, we anticipate that these compounds could have broad medical applicability in patients with COVID-19 and other coronavirus infections.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Anti-Retroviral Agents><Antigenic Determinants><Antiretroviral Agents><Antiviral Agents><Antiviral Drugs><Antiviral Therapy><Antivirals><Binding Determinants><Bioavailable><Body Tissues><Bypass><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 patient><COVID-19 positive patient><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><CV19><Cell Line><CellLine><Cessation of life><China><Clinical Treatment Moab><CoV-2><CoV2><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><DNA-Dependent RNA Polymerases><DNA-Directed RNA Polymerase><Data><Death><Development><Dose><Drug Kinetics><Drug Precursors><Effectiveness><Epidemic><Epitopes><Esters><Event><Evolution><Food and Drug Administration><GS-5734><Generations><Hepatotoxic effect><Hepatotoxicity><Hospital Admission><Hospitalization><Human><Immune response><Immunity><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><In Vitro><Individual><Infection><Intermediary Metabolism><Intervention><Intervention Strategies><Liver><Liver Toxicity><Lytotoxicity><Mainland China><Medical><Medicinal Chemistry><Metabolic Processes><Metabolism><Modality><Modeling><Modern Man><Monoclonal Antibodies><Nucleosides><Oral><Oral Administration><Oral Drug Administration><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacokinetics><Population><Pro-Drugs><Prodrugs><Proteins><RNA Polymerases><Reporting><Research Resources><Resources><Rodent><Rodentia><Rodents Mammals><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site><Strains Cell Lines><Structure><Sustainable Development><Synthesis Chemistry><Synthetic Chemistry><Testing><Therapeutic><Tissues><Toxic effect><Toxic effect on liver cells><Toxicities><USFDA><United States Food and Drug Administration><Vaccination><Vaccines><Variant><Variation><Veklury><Viral><Virus><Virus Replication><Wuhan coronavirus><access to vaccination><access to vaccines><anti-retroviral><anti-viral agents><anti-viral drugs><anti-viral therapy><anti-virals><antiretroviral><base><cell type><corona virus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><cultured cell line><cytotoxicity><design><designing><developmental><falls><hCoV19><hepatic body system><hepatic organ system><hepatic toxicity><hepatoxicity><host response><immune system response><immunoresponse><improved><indexing><interventional strategy><intraoral drug delivery><lead candidate><mAbs><nCoV2><novel><nucleoside analog><nucleoside diphosphate><nucleoside triphosphate><parenteral administration><parenteral delivery><parenteral infusion><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><phosphonate><remdesivir><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><triphosphate><tripolyphosphate><vaccination access><vaccination availability><vaccine access><vaccine availability><vaccine efficacy><viral infectious disease treatment><viral multiplication><viral replication><viral transmission><virus multiplication><virus transmission>